RXST

RxSight (RXST) beat EPS expectations with a loss of $0.21 per share versus consensus estimate of $0.29, representing a 27.59% earnings surprise. However, the company missed revenue estimates, posting $24.59 million versus the expected amount, down from $30.34 million year-over-year.

The stock has underperformed significantly, down 53.9% year-to-date. RxSight holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

K2 Vision, a Pacific Northwest and Arizona-based vision correction practice, has completed 5,000 Light Adjustable Lens (LAL) procedures and been recognized by RxSight as the world's highest-volume LAL practice. The LAL is the first lens implant that can be adjusted after placement through noninvasive light treatments, allowing for customized vision correction based on patient needs.